Study of BHV-1400 in IgA Nephropathy
ConditionIgA Nephropathy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBiohaven Therapeutics Ltd.
About this trial
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility criteria
Qualifiers
None
Disqualifiers
Any secondary IgAN
Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Trial design
Treatments tested in this trial
- BHV-1400
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
15United Kingdom
Site-007LE5 4PW, Leicester United Kingdom
United States
Connecticut
Site-00106030, Farmington United States
Florida
Site-00333016, Miami Lakes United States
Site-01133172, Miami Lakes United States
Sponsors and collaborators
Biohaven Therapeutics Ltd.
Lead sponsor
Source ClinicalTrials.gov